{"filing":{"accession_number":"0001193125-26-277511","cik":"0001796280","ticker":"ORIC","company_name":"Oric Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-06-22","report_date":null,"primary_document":"d103876d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1796280/000119312526277511/d103876d8k.htm"},"events":[{"id":12729,"run_id":11294,"accession_number":"0001193125-26-277511","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"Oric Pharmaceuticals held its annual meeting of stockholders on June 18, 2026, with voting results on five proposals: election of Class III directors (Jacob M. Chacko and Mardi C. Dier), ratification of KPMG LLP as independent auditor, approval of the amended 2020 Equity Incentive Plan, advisory approval of named executive officer compensation, and advisory vote on frequency of future compensation votes. All proposals passed.","company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","filing_date":"2026-06-22","form":"8-K","submitted_at":null,"items":[{"id":9662,"accession_number":"0001193125-26-277511","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on stockholder approval and amendment of the 2020 Equity Incentive Plan, which governs compensatory arrangements for directors and officers. The amendments modify share reserve provisions, incentive stock option limits, and award exchange/cancellation mechanics—all core elements of executive compensation plans. This falls squarely within Item 5.02(e) compensation disclosure and is material to investors assessing the company's equity incentive structure and dilution profile.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T20:47:50.358193+00:00","company_name":"","ticker":null,"filing_date":""},{"id":9663,"accession_number":"0001193125-26-277511","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 discloses the results of Oric Pharmaceuticals' June 18, 2026 annual meeting of stockholders, including voting outcomes on five proposals: election of Class III directors (Jacob M. Chacko and Mardi C. Dier), ratification of KPMG LLP as independent auditor, approval of the amended 2020 Equity Incentive Plan, advisory approval of named executive officer compensation, and advisory vote on frequency of future compensation votes. The detailed vote tallies and passage of all proposals constitute material shareholder voting results required under Item 5.07.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T20:47:50.358193+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":9662,"accession_number":"0001193125-26-277511","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on stockholder approval and amendment of the 2020 Equity Incentive Plan, which governs compensatory arrangements for directors and officers. The amendments modify share reserve provisions, incentive stock option limits, and award exchange/cancellation mechanics—all core elements of executive compensation plans. This falls squarely within Item 5.02(e) compensation disclosure and is material to investors assessing the company's equity incentive structure and dilution profile.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T20:47:50.358193+00:00","company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","filing_date":"2026-06-22"},{"id":9663,"accession_number":"0001193125-26-277511","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 discloses the results of Oric Pharmaceuticals' June 18, 2026 annual meeting of stockholders, including voting outcomes on five proposals: election of Class III directors (Jacob M. Chacko and Mardi C. Dier), ratification of KPMG LLP as independent auditor, approval of the amended 2020 Equity Incentive Plan, advisory approval of named executive officer compensation, and advisory vote on frequency of future compensation votes. The detailed vote tallies and passage of all proposals constitute material shareholder voting results required under Item 5.07.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T20:47:50.358193+00:00","company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","filing_date":"2026-06-22"}]}